Celldex Therapeutics (United States)

Recent papers from Celldex Therapeutics (United States)

1. A Randomized Placebo-Controlled Trial of HTD1801 Monotherapy in Participants With Type 2 DiabetesDiabetes Care · 2026
2. Characteristics of dermal fibroblasts and their biotherapeutic value in musculoskeletal system diseasesFrontiers in Bioengineering and Biotechnology · 2026
3. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialThe Lancet Oncology · 2026
4. Prophylactic Active Immunization Protects against Xylazine-Induced Pharmacological Effects in RatsJournal of Medicinal Chemistry · 2026
5. Reprogramming tumor-associated immune cells with Z-007, a first-in-class systemic TLR7/8/9 agonist.Journal of Clinical Oncology · 2026
6. Differential susceptibility of hair colour changes after barzolvolimabJournal of the European Academy of Dermatology and Venereology · 2026
7. First-in-human study of AAV6-NeuroD1 trans-differentiation therapy in recurrent malignant glioma.Journal of Clinical Oncology · 2026
8. Homozygous RFC1 AAGGG Repeat Expansions Are Common in Idiopathic Peripheral NeuropathyAnnals of Neurology · 2026
9. Abstract 4539: A MUC1-C-targeting ADC exhibits potent antitumor activity against neuroendocrine prostate cancer in both intact and testosterone-depleted preclinical modelsCancer Research · 2026
10. Abstract 5675: MUC1-C-directed exatecan ADC induces genotoxic stress and transcriptional suppression of UPR-inflammatory pathways in metastatic colorectal cancer.Cancer Research · 2026
11. Abstract 3175: Comparative efficacy of MUC1-C (XYA02) and MUC1-N (PankoMab, DS-3939a analog) antibody-drug conjugates in preclinical NSCLCCancer Research · 2026
12. Abstract 3142: Genomic determinants of response to the Wnt/Beta-catenin condensate modulator DPTX3186 in gastric cancer PDX models and implications for clinical developmentCancer Research · 2026
13. Abstract 5393: Preclinical efficacy and safety profile of NPX125, a novel ADC targeting B7-H7.Cancer Research · 2026
14. Abstract 6779: Molecular glue degraders of the RNA binding protein HuR to treat BRAF-mutant colorectal cancerCancer Research · 2026
15. Abstract A052: Safety, immunogenicity and resistance of in situ Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trialCancer Immunology Research · 2026
16. Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticariaJournal of Allergy and Clinical Immunology · 2026
17. Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma ModelsJournal of Functional Biomaterials · 2025
18. CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunityScience Immunology · 2025
19. Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non−small cell lung cancer: 5-Year outcomesJTCVS Open · 2025
20. On the Kinetics of Human Skin Mast Cell Depletion and Repopulation Following KIT InhibitionAllergy · 2025